Alethio Therapeutics has raised $90 million (£67 million) to take a new essential thrombocythemia (ET) antibody, ATX-011, into its first human studies. The Oxford, UK, company announced the oversubscribed Series A financing on November 5, 2026. It is real momentum for ET research. It is not a new treatment option. Alethio describes ATX-011 as still in […]
MRD Monitoring in MPN: What It Means for Your Care
If you live with polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF), you may have heard your doctor mention your “mutation” or “allele burden.” A new review takes a close look at MRD monitoring in MPN, and I want to walk you through it in plain language. The review, by Gary Markey and Stephen […]
Interferon for Myelofibrosis: 2025 Study Challenges “Watch and Wait”
by David Wallace For years, the medical community has told us the same thing when we’re diagnosed with early-stage myeloproliferative neoplasms: “Let’s watch and wait.” The thinking was straightforward: why expose someone to treatment side effects when they’re not yet symptomatic? But a study published this December in the journal Cancers is challenging that entire […]
Paving the way to improve therapy for MPNs
Megan Bywater & Steven W. Lane, Nature Communications volume 13, Article number: 5025, Published: August 26, 2022 Long-acting IFNα induces durable molecular responses in myeloproliferative neoplasms. Emerging studies, including Saleiro et al. recently published in Nature Communications, have identified promising candidates that may synergize with IFNα by targeting stem cell function or feedback loops that mediate […]





